These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 16148737)

  • 1. Multiple sclerosis and Hashimoto thyroiditis: two cases.
    Petek-Balci B; Yayla V; Ozer F
    Neurologist; 2005 Sep; 11(5):301-4. PubMed ID: 16148737
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Possibilities and risks of the monoclonal antibody alemtuzumab as a new treatment option for multiple sclerosis].
    Warnke C; Kieseier BC; Zettl U; Hartung HP
    Nervenarzt; 2009 Apr; 80(4):468-74. PubMed ID: 19296065
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Alemtuzumab and multiple sclerosis: therapeutic application.
    Minagar A; Alexander JS; Sahraian MA; Zivadinov R
    Expert Opin Biol Ther; 2010 Mar; 10(3):421-9. PubMed ID: 20095876
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Autoimmune disease after alemtuzumab treatment for multiple sclerosis in a multicenter cohort.
    Cossburn M; Pace AA; Jones J; Ali R; Ingram G; Baker K; Hirst C; Zajicek J; Scolding N; Boggild M; Pickersgill T; Ben-Shlomo Y; Coles A; Robertson NP
    Neurology; 2011 Aug; 77(6):573-9. PubMed ID: 21795656
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Thyroid dysfunction from antineoplastic agents.
    Hamnvik OP; Larsen PR; Marqusee E
    J Natl Cancer Inst; 2011 Nov; 103(21):1572-87. PubMed ID: 22010182
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Buzz around Campath proof-of-concept trial in MS.
    Osborne R
    Nat Biotechnol; 2009 Jan; 27(1):6-8. PubMed ID: 19131976
    [No Abstract]   [Full Text] [Related]  

  • 7. [Alemtuzumab in early multiple sclerosis].
    Killestein J; Polman CH
    Ned Tijdschr Geneeskd; 2009 Jan; 153(1-2):46. PubMed ID: 19198214
    [No Abstract]   [Full Text] [Related]  

  • 8. The window of therapeutic opportunity in multiple sclerosis: evidence from monoclonal antibody therapy.
    Coles AJ; Cox A; Le Page E; Jones J; Trip SA; Deans J; Seaman S; Miller DH; Hale G; Waldmann H; Compston DA
    J Neurol; 2006 Jan; 253(1):98-108. PubMed ID: 16044212
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Severe proximal myopathy secondary to Hashimoto's thyroiditis.
    Jervis W; Shah N; Mongolu SK; Sathyapalan T
    BMJ Case Rep; 2019 Jul; 12(7):. PubMed ID: 31352397
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Monoclonal antibodies in the treatment of multiple sclerosis.
    Di Pauli F; Berger T; Reindl M
    Curr Med Chem; 2009; 16(36):4858-68. PubMed ID: 19929782
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Transient increase in symptoms associated with cytokine release in patients with multiple sclerosis.
    Moreau T; Coles A; Wing M; Isaacs J; Hale G; Waldmann H; Compston A
    Brain; 1996 Feb; 119 ( Pt 1)():225-37. PubMed ID: 8624684
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pulsed monoclonal antibody treatment and autoimmune thyroid disease in multiple sclerosis.
    Coles AJ; Wing M; Smith S; Coraddu F; Greer S; Taylor C; Weetman A; Hale G; Chatterjee VK; Waldmann H; Compston A
    Lancet; 1999 Nov; 354(9191):1691-5. PubMed ID: 10568572
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical trials with CAMPATH-I and other monoclonal antibodies.
    Hale G; Phillips JM
    Biochem Soc Trans; 1995 Nov; 23(4):1057-63. PubMed ID: 8654681
    [No Abstract]   [Full Text] [Related]  

  • 14. Prevalence of autoimmune thyroiditis and non-immune thyroid disease in multiple sclerosis.
    Niederwieser G; Buchinger W; Bonelli RM; Berghold A; Reisecker F; Költringer P; Archelos JJ
    J Neurol; 2003 Jun; 250(6):672-5. PubMed ID: 12796827
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Melanoma following treatment with alemtuzumab for multiple sclerosis.
    Pace AA; Zajicek JP
    Eur J Neurol; 2009 Apr; 16(4):e70-1. PubMed ID: 19222552
    [No Abstract]   [Full Text] [Related]  

  • 16. Hoffmann's syndrome and pituitary hyperplasia in an adolescent secondary to Hashimoto thyroiditis.
    Cebeci AN; Güven A; Saltik S; Mesci C
    J Pediatr Endocrinol Metab; 2013; 26(7-8):747-51. PubMed ID: 23612591
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Alemtuzumab (Millennium/ILEX).
    Dumont FJ
    Curr Opin Investig Drugs; 2001 Jan; 2(1):139-60. PubMed ID: 11527007
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Alemtuzumab.
    Bates D
    Int MS J; 2009 Sep; 16(3):75-6. PubMed ID: 19899240
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A case of thyroiditis during natalizumab therapy for multiple sclerosis.
    Oddo S; Laroni A; Uccelli A; Giusti M
    J Endocrinol Invest; 2011 May; 34(5):408-9. PubMed ID: 21677508
    [No Abstract]   [Full Text] [Related]  

  • 20. Remission of chronic inflammatory demyelinating polyneuropathy after alemtuzumab (Campath 1H).
    Hirst C; Raasch S; Llewelyn G; Robertson N
    J Neurol Neurosurg Psychiatry; 2006 Jun; 77(6):800-2. PubMed ID: 16705208
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.